Med Page Today
SEPTEMBER 4, 2024
(MedPage Today) -- Health professionals often perform the "eyeball test" when they first meet a patient. Through the power of observation, pixels of information are gathered quickly and often unconsciously to determine whether a patient is unwell.
HCPLive
SEPTEMBER 4, 2024
An expert on fibromyalgia discusses concerns associated with long-term use of medications.
Science Daily - Heart Disease
SEPTEMBER 4, 2024
A new study has found that regular mobile phone use was positively associated with incident cardiovascular diseases risk. In addition, this association was partly attributed to poor sleep, psychological distress, and neuroticism.
HCPLive
SEPTEMBER 4, 2024
Rizk discusses the recent FDA accelerated approval of iptacopan (Fabhalta) and reflects on the significance of other therapeutic developments in IgAN.
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Science Daily - Heart Disease
SEPTEMBER 4, 2024
Our risk of developing atherosclerosis -- 'furring' of the arteries -- can begin much earlier in life than was previously thought, highlighting the need to keep cholesterol levels low even when we are young, new research has discovered.
NEJM Journal Watch - Cardiology
SEPTEMBER 4, 2024
The nonsteroidal mineralocorticoid receptor antagonist improved this population's rate of worsening heart failure events in a randomized trial.
Cardiovascular Update brings together the best content for cardiovascular medicine professionals from the widest variety of industry thought leaders.
NEJM Journal Watch - Cardiology
SEPTEMBER 4, 2024
Invasive and conservative strategies had similar outcomes in a randomized trial involving patients age 75 years or older with non–ST-segment elevation myocardial infarction.
The New England Journal of Medicine
SEPTEMBER 4, 2024
In a 57-year-old man with chest pain, an ECG obtained by EMS showed widespread ST-segment depressions. At the hospital, left main coronary-artery stenosis was seen on angiography (shown in a video).
HCPLive
SEPTEMBER 4, 2024
Ahmad Masri, MD, MS, highlights a trio of studies from ESC Congress 2024 examining use of aficamten in hypertrophic cardiomyopathy.
Journal of Cardiothoracic Surgery
SEPTEMBER 4, 2024
Type A acute aortic dissection (TAAAD) is a deadly condition that demands immediate surgery, because it involves a critically. The mortality and morbidity associated with it are significant, and it is vital th.
HCPLive
SEPTEMBER 4, 2024
A post-hoc analysis of the STEP trials found semaglutide for weight management doesn’t increase depression or suicidal thoughts in individuals without major mental disorders.
Journal of Cardiothoracic Surgery
SEPTEMBER 4, 2024
To analyze the influencing factors of postoperative thrombocytopenia in critically ill patients with heart disease and construct a nomogram prediction model.
HCPLive
SEPTEMBER 4, 2024
This August 2024 month in review spotlights HCPLive’s top coverage of hepatic pipeline news and recent research in liver disease, HCV, and more.
CardiacWire
SEPTEMBER 4, 2024
Nearly a year after Bayer halted its OCEANIC-AF trial , the study’s ESC 2024 presentation revealed new insights into asundexian’s AFib stroke-prevention challenges and what they might mean for Factor XI inhibitors. Factor XI/XIa inhibitors have sparked optimism for their potential to become safer antithrombotics by avoiding anticoagulants’ bleeding risks.
HCPLive
SEPTEMBER 4, 2024
Ahmad Masri, MD, MS, discusses the results of a SEQUOIA-HCM substudy leveraging cardiac magnetic resonance to assess structural changes associated with aficamten use in HCM.
DAIC
SEPTEMBER 4, 2024
tim.hodson Wed, 09/04/2024 - 16:08 Sept. 1 — September is Peripheral Artery Disease (PAD) Awareness Month, a time to educate and empower people to act against the most debilitating disease they haven’t heard of — or know that they have. PAD affects more than 10 million Americans and is a factor in 400 amputations each day, making it the largest cause of nontraumatic amputations in the United States.
HCPLive
SEPTEMBER 4, 2024
The biosimilars month in review highlights recent data demonstrating clinical equivalence and efforts to improve their access.
Becker's Hospital Review - Cardiology
SEPTEMBER 4, 2024
An AI-enabled stethoscope identified heart failure in two times as many pregnant patients when compared to traditional screening, according to a study published Sept. 2 in Nature Medicine.
DAIC
SEPTEMBER 4, 2024
tim.hodson Wed, 09/04/2024 - 15:34 Aug. 29, 2024 – Jupiter Endovascular, Inc., recently announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational Device Exemption application for the SPIRARE II U.S. pivotal study (NCT06576427). The pivotal trial will study the Vertex Pulmonary Embolectomy System, which incorporates Jupiter’s Endoportal Control platform technology into an endovascular procedure intended to treat Acute Pulmonary Embolism (PE) with an unprece
HCPLive
SEPTEMBER 4, 2024
Panelists discuss how treating hypercortisolism in patients may have long-term effects on glycemic control and overall health, potentially influencing future standards of care for difficult-to-control Type 2 diabetes, while emphasizing the need for clinicians to carefully manage such patients as ongoing research continues.
DAIC
SEPTEMBER 4, 2024
tim.hodson Wed, 09/04/2024 - 15:53 Sept. 1, 2024 — Researchers at UTHealth Houston have identified genetic variants linked to a rare form of bicuspid aortic valve disease that affects young adults and can lead to dangerous and potentially life-threatening aortic complications. The study was published in the American Journal of Human Genetics. “We previously found that young individuals who present due to early onset thoracic aortic dissections are more likely to have bicuspid aortic valves and
HCPLive
SEPTEMBER 4, 2024
This August 2024 month in review highlights new recommendations from the USPSTF, FDA approval of a treatment for chronic GVHD, and Phase 2 data for severe HDFN.
Physiologically Speaking
SEPTEMBER 4, 2024
Greetings! David Roche is a decorated trail runner, coach, and co-founder of SWAP Running. He's a two-time national champion and a three-time Team USA member, and he recently set the course record at the Leadville 100 trail run with a time of 15 hours, 26 minutes, 34 seconds. David and his wife, Megan Roche, M.D., offer coaching that blends science, training theory, and a philosophy of joy and long-term growth for all athletes.
HCPLive
SEPTEMBER 4, 2024
The FDA approved neffy for treating severe allergic reactions in people over 33 kg in August 2024.
HeartRhythm
SEPTEMBER 4, 2024
The Efficacy of Delayed Enhancement MRI-Guided Fibrosis Ablation vs Conventional Catheter Ablation of Atrial Fibrillation randomized trial showed no difference in atrial fibrillation (AF) recurrence with additional delayed enhancement magnetic resonance imaging (DE-MRI) fibrosis-targeted ablation to pulmonary vein isolation (PVI) in persistent AF.
HCPLive
SEPTEMBER 4, 2024
This month in review highlights MDMA-assisted therapy coverage, experiences with zuranolone a year after its approval, and early positive data on potential treatments.
HeartRhythm
SEPTEMBER 4, 2024
Vascular access site complications are the most frequent complications of percutaneous catheter ablation (CA) of ventricular arrhythmias (VAs). Whether arterial/venous vascular closure devices (VCDs) prevent vascular complications is unknown.
HCPLive
SEPTEMBER 4, 2024
This Month in Review summarizes some of the most significant stories covered in the month of August in the pulmonary health space, including new research and FDA news.
Stroke: Vascular and Interventional Neurology
SEPTEMBER 4, 2024
Stroke: Vascular and Interventional Neurology, Volume 4, Issue 6 , November 1, 2024. BackgroundMechanical thrombectomy is the standard of care in acute ischemic stroke with anterior large vessel occlusion presenting within 6 hours of symptom onset, but complications do exist. We assessed the feasibility of a hybrid simulationbased workshop at a national meeting for interventional neurology trainees focused on the management of acute ischemic stroke and tissueplasminogen activatorrelated hemorrha
Journal of Cardiothoracic Surgery
SEPTEMBER 4, 2024
Cardiac fibromas are extremely rare in adults. The preferred treatment is surgical resection, but antiarrhythmic medications or heart transplantation have also been used previously. The cardiac imaging, partic.
HeartRhythm
SEPTEMBER 4, 2024
Heart failure with preserved ejection fraction (HFpEF) and atrial fibrillation (AF) are comorbid conditions that are increasingly prevalent and have a high socioeconomic burden. This article discusses their shared pathophysiology, focusing on the triad of hypertension, obesity, and aging.We highlight the misperception that pharmacologic heart rate lowering is beneficial, which has resulted in an overprescription of beta-blockers in HFpEF and AF.
NEJM Journal Watch - Cardiology
SEPTEMBER 4, 2024
In a multicenter randomized trial, edoxaban monotherapy reduced nonfatal major and clinically relevant nonmajor bleeding without excess risk for ischemic events.
HeartRhythm
SEPTEMBER 4, 2024
Transthyretin cardiac amyloidosis (ATTR-CA) is the most common type of amyloid cardiomyopathy which frequently presents with cardiac arrythmias. Recent data suggest that sodium-glucose contransporter-2 inhibitors (SGLT2i) may mitigate development of cardiac arrythmias in patients with heart failure with preserved ejection fraction and patients with ischemic heart disease [1].
NEJM Journal Watch - Cardiology
SEPTEMBER 4, 2024
The RNA silencer reduced the risk for death and cardiovascular events in both hereditary and wild-type disease.
American College of Cardiology
SEPTEMBER 4, 2024
In this week’s View, Dr. Eagle looks at the kidney and cardiovascular effectiveness of SGLT2 inhibitors versus GLP-1 receptor agonists in type 2 diabetes. He then explores the prognostic ability of diffusion-weighted brain MRI lesions after TAVR.
The American Journal of Cardiology
SEPTEMBER 4, 2024
Publication date: Available online 4 September 2024 Source: The American Journal of Cardiology Author(s): Marcos García-Guimarães, Manel Sabaté, Ignacio Cruz-González, Ernesto Valero, Teresa Bastante, Fernando Alfonso, investigators of the Spanish Registry on Spontaneous Coronary Artery Dissection
Expert insights. Personalized for you.
145 
Let's personalize your content